David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog
David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog
David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Case 1:09-cv-04665-<strong>DL</strong>C Document 49-2 Filed 03/30/2010 Page 16 of 451-105.1-113.100. Teva denies the allegations in Paragraph 100.101. Teva denies the allegations in Paragraph 101.102. Teva denies the allegations in Paragraph 102.103. Teva denies the allegations in Paragraph 103.104. Teva denies the allegations in Paragraph 104.105. Teva denies the allegations in Paragraph 105.COUNT XI(INFRINGEMENT OF THE METHOD CLAIMS OF THE ‘404 PATENTUNDER 35 U.S.C. § 271(b))106. Teva incorporates by reference as if stated fully herein its responses to Paragraphs107. Teva denies the allegations in Paragraph 107.108. Teva denies the allegations in Paragraph 108.109. Teva denies the allegations in Paragraph 109.110. Teva denies the allegations in Paragraph 110.111. Teva denies the allegations in Paragraph 111.112. Teva denies the allegations in Paragraph 112.113. Teva denies the allegations in Paragraph 113.COUNT XII(INFRINGEMENT OF THE METHOD CLAIMS OF THE ‘043 PATENTUNDER 35 U.S.C. § 271(b))114. Teva incorporates by reference as if stated fully herein its responses to Paragraphs115. Teva denies the allegations in Paragraph 115.116. Teva denies the allegations in Paragraph 116.9067383.115
Change language